Skip to main content

Advertisement

SpringerLink
Log in

Target blood pressure for antihypertensive therapy in patients with proteinuric renal disease

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The Modification of Diet in Renal Disease (MDRD) study showed for the first time that controlling blood pressure is critically important in slowing the progression of proteinuric renal disease (24-h proteinuria of 1.0 g or more). Furthermore, it was found that the greater proteinuria, the more important it was to achieve excellent blood pressure control. The MDRD analysis also suggested that this paradigm may be particularly important for blacks with proteinuric renal disease. Surprisingly, the MDRD data showed that a blood pressure of 125/75 mm Hg was superior to a blood pressure of 135/85 mm Hg in slowing the progression of renal disease. Thus, so-called hypercontrol of blood pressure is needed to slow the progression of proteinuric renal disease. Studies in patients with diabetic glomerulosclerosis also have provided evidence as to the importance of achieving the low blood pressure goal to slow the progression of the glomerulopathy. In summary, strict control of blood pressure (125/75 mm Hg or less, if tolerated) is recommended to slow the progression of proteinuric renal disease. Furthermore, the greater the proteinuria, the more important it is to achieve this target blood pressure to slow the progression of renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 1998, 35:670–674. This article provides an extensive review of the evidence showing that hypertension is associated with the progression of renal disease.

    Google Scholar 

  2. Klahr S, Levey AS, Beck GJ, et al.: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877–884.

    Article  PubMed  CAS  Google Scholar 

  3. Peterson JC, Adler S, Burkart JM, et al., for the Modification of Diet in Renal Disease (MDRD) Study Group: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.

    PubMed  CAS  Google Scholar 

  4. Burton C, Harris KPG: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996, 27:765–775.

    PubMed  CAS  Google Scholar 

  5. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997, 51:2–15.

    Article  PubMed  CAS  Google Scholar 

  6. Abbate M, Zoja C, Rottoli D, et al.: Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 1999, 10:804–813. The data discussed in Reference 5 are updated in this article and new data on complement and the progression of renal disease are provided.

    PubMed  CAS  Google Scholar 

  7. Apperloo AJ, deZeeuw D, deJong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int 1994, 45(Suppl 45):S174-S178.

    CAS  Google Scholar 

  8. Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994, 45(Suppl 45):S145-S149.

    CAS  Google Scholar 

  9. Hebert LA, Bain RP, Verme D, et al., for the Collaborative Study Group: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994, 46:1688–1693.

    Article  PubMed  CAS  Google Scholar 

  10. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645–651. This work is discussed in some detail in this review.

    Article  PubMed  CAS  Google Scholar 

  11. Breyer-Lewis J, Burl T, Bain R, Lewis EJ, for the Collaborative Study Group: Effect of intensive blood pressure control on the course of type I diabetic nephropathy. Am J Kidney Dis, in press.: Please update.

  12. Coggins CH, Breyer JA, Caggiula AW, et al., for the Modification of Diet in Renal Disease (MDRD) Study Group: Women and men in the MDRD study: a gender analysis of participation in the study protocol and of renal outcomes. Ann Intern Med, in press.: Please update.

  13. Hebert LA, Kusek JW, Greene T, et al., for the Modification of Diet in Renal Disease Study Group: Effects of blood pressure control on progressive renal diseases in blacks and whites. Hypertension 1997, 30:428–435.

    PubMed  CAS  Google Scholar 

  14. Mejia AD, Egan BM, Schork NJ, Zweifler AJ: Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatmentresistant hypertension. Ann Intern Med 1990, 112:270–277.

    PubMed  CAS  Google Scholar 

  15. Fang J, Madhavan S, Cohen H, Alderman MH: Isolated diastolic hypertension. A favorable finding among young and middle-aged hypertensive subjects. Hypertension 1995, 26:377–382.

    PubMed  CAS  Google Scholar 

  16. Blank SG, Mann SJ, James GD, et al.: Isolated elevation of diastolic blood pressure. Real or artifactual? Hypertension 1995, 26:383–389.

    PubMed  CAS  Google Scholar 

  17. Klahr S, Breyer JA, Beck GJ, et al., for the Modification of Diet in Renal Disease Study Group: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. J Am Soc Nephrol 1995, 5:2037–2047.

    PubMed  CAS  Google Scholar 

  18. Hall WD, Kusek JW, Kirk KA, et al., for the African-American Study of Kidney Disease and Hypertension Pilot Study Investigators: Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: The African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1997, 29:720–728.

    PubMed  CAS  Google Scholar 

  19. VanEssen GG, Apperloo AJ, Rensma PL, et al.: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int 1997, 52(Suppl 63):S58-S62.

    Google Scholar 

  20. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  21. Ruggenenti P, Perna A, Mosconi, et al., for the GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857–1863.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ohio State University, 43210, Columbus, Ohio, USA

    Lee A. Hebert MD

Authors
  1. Lee A. Hebert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hebert, L.A. Target blood pressure for antihypertensive therapy in patients with proteinuric renal disease. Current Science Inc 1, 454–460 (1999). https://doi.org/10.1007/s11906-999-0063-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-999-0063-0

Keywords

Search

Navigation